Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18774123 | DOSING REGIMEN FOR TREATING INFLAMMATORY BOWEL DISEASE | July 2024 | April 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18067948 | CHIMERIC POLYPEPTIDE ASSEMBLY AND METHODS OF MAKING AND USING THE SAME | December 2022 | January 2024 | Allow | 12 | 0 | 1 | No | No |
| 17929655 | COMBINATIONS OF IMMUNOTHERAPIES AND USES THEREOF | September 2022 | March 2025 | Abandon | 31 | 3 | 0 | Yes | No |
| 17719894 | FUSION PROTEINS THAT FACILITATE CANCER CELL DESTRUCTION | April 2022 | April 2025 | Allow | 36 | 0 | 1 | No | No |
| 17689388 | CD19 BINDING AGENTS AND USES THEREOF | March 2022 | January 2025 | Abandon | 34 | 0 | 1 | No | No |
| 17682633 | CELL SURFACE COUPLING OF NANOPARTICLES | February 2022 | May 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17680174 | Anti-CD30 monoclonal antibodies and chimeric antigen receptors | February 2022 | August 2023 | Allow | 18 | 1 | 1 | Yes | No |
| 17670718 | METHOD FOR CONTROLLING AFFINITY OF ANTIBODY FOR ANTIGEN, ANTIBODY WHOSE AFFINITY FOR ANTIGEN HAS BEEN ALTERED, AND ITS PRODUCTION METHOD | February 2022 | February 2025 | Allow | 36 | 0 | 1 | No | No |
| 17666018 | Humanized anti-DKK2 antibody and uses thereof | February 2022 | December 2024 | Abandon | 35 | 0 | 1 | No | No |
| 17645737 | VACCINE | December 2021 | March 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17645741 | VACCINE | December 2021 | November 2022 | Allow | 11 | 2 | 0 | Yes | No |
| 17542948 | Anti-TfR1 Antibody MAb11-22.1 Conjugates for Cancer Treatment | December 2021 | January 2024 | Allow | 26 | 1 | 1 | Yes | No |
| 17530211 | GENETICALLY MODIFIED NK-92 CELLS HAVING A SAFETY SWITCH | November 2021 | April 2025 | Allow | 40 | 2 | 1 | No | No |
| 17525512 | HUMAN MONOCLONAL ANTIBODY HUMAN CD134 (OX40) AND METHODS OF MAKING AND USING SAME | November 2021 | February 2025 | Allow | 39 | 1 | 0 | No | No |
| 17518123 | CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA AND METHODS OF USE THEREOF | November 2021 | November 2024 | Allow | 37 | 1 | 0 | No | No |
| 17488698 | METHOD FOR GENERATING AVID-BINDING MULTISPECIFIC ANTIBODIES | September 2021 | July 2025 | Allow | 45 | 1 | 0 | Yes | No |
| 17405104 | ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) IMMUNOADHESIN MICROBODY | August 2021 | February 2024 | Allow | 30 | 0 | 1 | Yes | No |
| 17431664 | Bispecific Fusion Protein Using Orthopoxvirus Major Histocompatibility Complex (MHC) Class I-Like Protein (OMCP) and Tumor-Specific Binding Partner | August 2021 | May 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17383765 | Anti-Abeta Antibodies | July 2021 | June 2025 | Allow | 46 | 3 | 1 | Yes | No |
| 17305577 | FUSION CONSTRUCTS AND METHODS OF USING THEREOF | July 2021 | August 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17351724 | Combination Therapy for the Treatment of Cancer | June 2021 | May 2025 | Abandon | 47 | 2 | 1 | No | No |
| 17328118 | CD70 Binding Molecules and Methods of Use Thereof | May 2021 | August 2024 | Allow | 39 | 1 | 1 | No | No |
| 17318590 | CELL SURFACE COUPLING OF NANOPARTICLES | May 2021 | October 2021 | Allow | 5 | 0 | 0 | No | No |
| 17317824 | AFFINITY ENTITIES COMPRISING A TCR-LIKE ANTIBODY BINDING DOMAIN WITH HIGH AFFINITY AND FINE SPECIFICITY AND USES OF SAME | May 2021 | November 2024 | Allow | 42 | 0 | 1 | Yes | No |
| 17307158 | COMPOSITIONS AND METHODS FOR TREATING CANCER | May 2021 | May 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17235805 | IMMUNOGLOBULIN VARIANTS AND USES THEREOF | April 2021 | August 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17227536 | Tetravalent Antibody-Drug Conjugates and Use Thereof | April 2021 | December 2023 | Allow | 32 | 0 | 0 | Yes | No |
| 17217839 | GENETICALLY MODIFIED NK-92 CELLS AND MONOCLONAL ANTIBODIES FOR THE TREATMENT OF CANCER | March 2021 | August 2021 | Allow | 5 | 1 | 0 | No | No |
| 17210124 | Antibodies Targeted to Fungal Cell Wall Polysaccharides | March 2021 | November 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17200322 | EGFR-DIRECTED CAR THERAPY FOR GLIOBLASTOMA | March 2021 | August 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17198179 | ANTI P2X7 RECEPTOR ANTIBODIES AND FRAGMENTS THEREOF | March 2021 | June 2024 | Allow | 39 | 1 | 1 | No | No |
| 17176858 | METHOD FOR ENGINEERING IMMUNOGLOBULINS | February 2021 | June 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17268174 | CANCER STEM CELL MARKER AND CANCER STEM CELL TARGETING DRUG | February 2021 | April 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17172694 | BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF | February 2021 | May 2022 | Allow | 15 | 2 | 1 | Yes | No |
| 17172700 | BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF | February 2021 | January 2025 | Allow | 48 | 1 | 1 | No | No |
| 17168100 | CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA AND METHODS OF USE THEREOF | February 2021 | October 2021 | Allow | 8 | 1 | 1 | Yes | No |
| 17264735 | MULTISPECIFIC TREG BINDING MOLECULES | January 2021 | October 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17151911 | BIOLOGICAL PRODUCTS | January 2021 | December 2023 | Abandon | 34 | 1 | 0 | No | No |
| 17150272 | B CELL MATURATION ANTIGEN BINDING PROTEINS | January 2021 | January 2024 | Allow | 36 | 1 | 1 | No | No |
| 17148337 | MULTISPECIFIC TREG BINDING MOLECULES | January 2021 | April 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17121622 | Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods | December 2020 | November 2024 | Abandon | 47 | 1 | 1 | No | No |
| 17104983 | CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | November 2020 | July 2024 | Allow | 44 | 2 | 2 | Yes | No |
| 17103190 | USE OF HEXOKINASE-2 IN DETECTION OF RARE TUMOR CELLS IN BODY FLUID SAMPLE AND KIT | November 2020 | October 2021 | Allow | 10 | 2 | 1 | No | No |
| 17084156 | THERAPEUTIC CD47 ANTIBODIES | October 2020 | October 2023 | Abandon | 36 | 0 | 1 | No | No |
| 17051731 | METHODS AND SYSTEMS FOR SELECTION AND TREATMENT OF PATIENTS WITH INFLAMMATORY DISEASES | October 2020 | November 2024 | Allow | 48 | 1 | 1 | Yes | No |
| 17078903 | TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR | October 2020 | January 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17048739 | Switch Molecule And Switchable Chimeric Antigen Receptor | October 2020 | January 2024 | Allow | 39 | 4 | 1 | Yes | No |
| 17032482 | DISRUPTION OF THE WAVE3 PROTEIN COMPLEX FOR SUPPRESSION OF INVASION AND METASTASIS | September 2020 | May 2023 | Allow | 32 | 0 | 1 | Yes | No |
| 17040426 | COMBINATION OF NEAR INFRARED PHOTOIMMUNOTHERAPY TARGETING CANCER CELLS AND HOST-IMMUNE ACTIVATION | September 2020 | January 2025 | Abandon | 52 | 3 | 1 | No | No |
| 16982723 | FC VARIANT COMPOSITIONS AND METHODS OF USE THEREOF | September 2020 | February 2024 | Abandon | 41 | 2 | 1 | No | No |
| 17025980 | PRODUCTION OF HETEROMULTIMERIC PROTEINS | September 2020 | June 2023 | Abandon | 32 | 1 | 0 | No | No |
| 17023835 | Modified Cell with Enhanced Functionality and Cellular Therapy thereof | September 2020 | July 2023 | Allow | 34 | 1 | 1 | Yes | No |
| 17021423 | Anti-MET Antibodies and Methods of Use Thereof | September 2020 | September 2023 | Allow | 36 | 1 | 1 | No | No |
| 16980816 | BISPECIFIC ANTIBODY CAR CELL IMMUNOTHERAPY | September 2020 | May 2024 | Abandon | 44 | 0 | 1 | No | No |
| 16980730 | MULTIFUNCTIONAL MOLECULES THAT BIND TO CALRETICULIN AND USES THEREOF | September 2020 | June 2024 | Allow | 45 | 1 | 1 | Yes | No |
| 16994795 | ANTI-MICA ANTIGEN BINDING FRAGMENTS, FUSION MOLECULES, CELLS WHICH EXPRESS AND METHODS OF USING | August 2020 | August 2023 | Allow | 36 | 1 | 1 | No | No |
| 16992497 | Inhibitors of the Interaction Between CLEC14A and Multimerin-2 for Inhibition of Angiogenesis | August 2020 | October 2023 | Allow | 38 | 1 | 1 | Yes | No |
| 16943313 | RECRUITING AGENT FURTHER BINDING AN MHC MOLECULE | July 2020 | September 2022 | Allow | 26 | 1 | 1 | No | No |
| 16943320 | METHODS AND COMPOSITIONS RELATING TO BISPECIFIC ANTI-CHI3L1 ANTIBODY REAGENTS FOR THE TREATMENT OF CANCER | July 2020 | January 2023 | Allow | 30 | 1 | 0 | No | No |
| 16940018 | MODIFIED NK-92 CELLS FOR TREATING CANCER | July 2020 | June 2023 | Allow | 34 | 1 | 1 | Yes | No |
| 16939265 | METHODS AND COMPOSITIONS RELATING TO ANTI-CHI3L1 ANTIBODY REAGENTS FOR THE TREATMENT OF CANCER | July 2020 | January 2023 | Allow | 30 | 1 | 0 | No | No |
| 16938576 | TROPHOBLAST GLYCOPROTEIN (5T4, TPBG) SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY | July 2020 | January 2024 | Allow | 42 | 2 | 0 | No | No |
| 16937285 | Proteins Comprising Kallikrein Related Peptidase 2 Antigen Binding Domains And Their Uses | July 2020 | September 2022 | Allow | 26 | 1 | 1 | Yes | No |
| 16960653 | COMPOSITIONS AND METHODS FOR TARGETING CLEC12A-EXPRESSING CANCERS | July 2020 | January 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 16959619 | COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY | July 2020 | April 2024 | Abandon | 45 | 0 | 1 | No | No |
| 16958915 | PRECISION MOLECULAR ADAPTOR SYSTEM FOR CAR-T IMMUNOTHERAPY | June 2020 | April 2024 | Abandon | 45 | 2 | 1 | No | No |
| 16903882 | GENETICALLY MODIFIED NK-92 CELLS AND MONOCLONAL ANTIBOIDES FOR THE TREATMENT OF CANCER | June 2020 | February 2021 | Allow | 8 | 2 | 1 | No | No |
| 16879978 | Acceptor Framework for CDR Grafting | May 2020 | March 2023 | Abandon | 34 | 0 | 1 | No | No |
| 16869322 | Humanized Anti-CD70 Binding Agents and Uses Thereof | May 2020 | September 2023 | Abandon | 41 | 1 | 1 | No | No |
| 16862042 | Tetravalent Antibody-Drug Conjugates and Use Thereof | April 2020 | February 2021 | Allow | 10 | 1 | 1 | Yes | No |
| 16755093 | TARGETED GENE INTEGRATION OF CRS INHIBITOR GENES FOR IMPROVED IMMUNE CELLS THERAPY | April 2020 | December 2024 | Allow | 56 | 3 | 1 | Yes | No |
| 16845030 | COMPOSITIONS AND METHODS OF USE FOR AUGMENTED IMMUNE RESPONSE AND CANCER THERAPY | April 2020 | March 2023 | Abandon | 35 | 0 | 1 | No | No |
| 16820504 | COMBINATION THERAPY OF ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES AND 4-1BB (CD137) AGONISTS | March 2020 | March 2023 | Allow | 36 | 1 | 1 | Yes | No |
| 16645785 | ANTIBODY-MEDIATED DELIVERY OF CAS9 TO MAMMALIAN CELLS | March 2020 | June 2024 | Abandon | 52 | 2 | 1 | No | No |
| 16498223 | ANTI-PD-L1/ANTI-PD-1 NATURAL ANTIBODY STRUCTURE-LIKE HETERODIMERIC BISPECIFIC ANTIBODY AND PREPARATION THEREOF | February 2020 | December 2022 | Allow | 39 | 1 | 1 | Yes | No |
| 16798104 | NUCLEIC ACID MOLECULES ENCODING CHIMERIC ANTIGEN RECEPTORS TARGETING G-PROTEIN COUPLED RECEPTOR | February 2020 | August 2023 | Allow | 42 | 1 | 1 | No | No |
| 16798151 | METHODS OF TREATMENTS USING CHIMERIC ANTIGEN RECEPTORS TARGETING G-PROTEIN COUPLED RECEPTOR | February 2020 | October 2020 | Allow | 8 | 1 | 0 | Yes | No |
| 16798059 | CHIMERIC ANTIGEN RECEPTORS TARGETING G-PROTEIN COUPLED RECEPTOR AND USES THEREOF | February 2020 | July 2023 | Allow | 41 | 1 | 1 | Yes | No |
| 16794119 | METHODS OF TREATING HEMATOLOGICAL DISORDERS, SOLID TUMORS, OR INFECTIOUS DISEASES USING NATURAL KILLER CELLS | February 2020 | January 2024 | Abandon | 47 | 2 | 1 | No | No |
| 16779011 | BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF | January 2020 | December 2020 | Allow | 10 | 1 | 1 | No | No |
| 16776349 | Fn14 Binding Proteins and Uses Thereof | January 2020 | March 2023 | Abandon | 38 | 1 | 0 | No | No |
| 16752231 | TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY | January 2020 | January 2023 | Abandon | 36 | 0 | 1 | No | No |
| 16742434 | Glycan-Interacting Compounds and Methods of Use | January 2020 | March 2023 | Abandon | 38 | 0 | 1 | No | No |
| 16733376 | MEANS AND METHODS FOR COUNTERACTING MYELOPROLIFERATIVE OR LYMPHOPROLIFERATIVE DISORDERS | January 2020 | November 2022 | Allow | 35 | 1 | 1 | No | No |
| 16730778 | PREDICTING CANCER PROGRESSION | December 2019 | December 2023 | Allow | 48 | 2 | 1 | Yes | No |
| 16728609 | CROSS-SPECIES-SPECIFIC PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALINXCD3, EPCAMXCD3, IGF-1RXCD3 OR FAPALPHAXCD3 BISPECIFIC SINGLE CHAIN ANTIBODY | December 2019 | February 2024 | Abandon | 49 | 2 | 1 | No | No |
| 16718729 | PD-L1 ANTIBODIES BINDING CANINE PD-L1 | December 2019 | May 2022 | Allow | 29 | 0 | 1 | No | No |
| 16704781 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | December 2019 | November 2022 | Allow | 35 | 1 | 1 | Yes | No |
| 16688173 | ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | November 2019 | March 2025 | Abandon | 60 | 4 | 1 | No | No |
| 16613343 | A CELL COMPRISING A CHIMERIC ANTIGEN RECEPTOR (CAR) | November 2019 | July 2023 | Abandon | 44 | 1 | 1 | No | No |
| 16675861 | CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2 | November 2019 | January 2023 | Allow | 39 | 1 | 1 | Yes | No |
| 16671395 | VACCINES WITH HIGHER CARBOHYDRATE ANTIGEN DENSITY AND NOVEL SAPONIN ADJUVANT | November 2019 | September 2022 | Allow | 35 | 1 | 1 | Yes | No |
| 16655646 | Antibodies Against Human NKG2D and Uses Thereof | October 2019 | February 2022 | Abandon | 28 | 0 | 1 | No | No |
| 16590358 | PGAM1 Inhibitors and Methods Related Thereto | October 2019 | April 2023 | Abandon | 43 | 1 | 1 | No | No |
| 16496144 | BIOMARKERS AND CAR T CELL THERAPIES WITH ENHANCED EFFICACY | September 2019 | June 2025 | Abandon | 60 | 3 | 1 | No | No |
| 16568638 | CD20-BINDING IMMUNOTOXINS FOR INDUCING CELLULAR INTERNALIZATION AND METHODS USING SAME | September 2019 | April 2022 | Abandon | 31 | 0 | 1 | No | No |
| 16546787 | ANTI-GPC3 ANTIBODY | August 2019 | March 2020 | Allow | 7 | 2 | 1 | No | No |
| 16541847 | GENETICALLY MODIFIED NK-92 CELLS AND MONOCLONAL ANTIBOIDES FOR THE TREATMENT OF CANCER | August 2019 | April 2020 | Allow | 8 | 1 | 1 | Yes | No |
| 16515870 | BCMA CHIMERIC ANTIGEN RECEPTORS | July 2019 | October 2023 | Allow | 51 | 3 | 1 | No | No |
| 16511600 | ANTI-IFNAR1 ANTIBODIES WITH REDUCED FC LIGAND AFFINITY | July 2019 | May 2023 | Abandon | 46 | 3 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DUFFY, BRADLEY.
With a 42.9% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 24.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner DUFFY, BRADLEY works in Art Unit 1643 and has examined 878 patent applications in our dataset. With an allowance rate of 53.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 37 months.
Examiner DUFFY, BRADLEY's allowance rate of 53.4% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by DUFFY, BRADLEY receive 1.75 office actions before reaching final disposition. This places the examiner in the 52% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by DUFFY, BRADLEY is 37 months. This places the examiner in the 13% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +54.6% benefit to allowance rate for applications examined by DUFFY, BRADLEY. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 18.7% of applications are subsequently allowed. This success rate is in the 11% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 38.7% of cases where such amendments are filed. This entry rate is in the 51% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 50% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 80.6% of appeals filed. This is in the 70% percentile among all examiners. Of these withdrawals, 62.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 59.3% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 6.5% of allowed cases (in the 92% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.4% of allowed cases (in the 73% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.